1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
- Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
- 2018
- A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
- 2011
- Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
- 2007
- Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
- 2005
- Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
- 2004
-
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
Stendahl, Maria LU ; Kronblad, Åsa LU ; Rydén, Lisa LU
; Emdin, S
; Bengtsson, N O
and Landberg, Göran
LU
(2004)
In British Journal of Cancer
90(10).
p.1942-1948
Mark